编号：DY2022-001 证券代码：300583 证券简称：赛托生物 山东赛托生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |---------------------------|-------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------| | | | | | | □特定对象调研 □分析师会议 | | | | □媒体采访 | 业绩说明会 | | 投资者关系活 动类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 | | | 参与单位名称 及人员姓名 | 参与公司 2021 | 年度业绩网上说明会活动的投资者 | | 时间 | 2022 年 5 月 6 日 | 15:00-17:00 | | 地点 | "全景•路演天下 ...

编号：DY2022-002 证券代码：300583 证券简称：赛托生物 山东赛托生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | | 投资者关系活 动类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | 其他（山东辖区上市公司 | 2022 年度投资者网上集体接待日活动） | | 参与单位名称 及人员姓名 | 参与公司 2022 | 年度投资者网上集体接待日活动的投资者 | | 时间 | 2022 年 11 月 16 日 | 14:00-16:00 ...

证券代码：300583 证券简称：赛托生物 编号：2022-081 山东赛托生物科技股份有限公司 关于参加山东辖区上市公司2022年度投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 为进一步加强与广大投资者的沟通交流，山东赛托生物科技股份有限公司 （以下简称"公司"）将参加由山东证监局、山东上市公司协会联合举办并由深 圳市全景网络有限公司承办的"山东辖区上市公司 2022 年度投资者网上集体接 待日"活动，现将有关事项公告如下： 本次投资者网上集体接待日活动将通过全景网平台线上交流方式举行，投资 者可以登录全景网"投资者关系互动平台"（http://ir.p5w.net/）参与本次活 动。活动时间为 2022 年 11 月 16 日（星期三）14:00-16:00。 届时公司总经理靳连标先生，董事、副总经理、董事会秘书李璐女士，财务 总监李福文先生等将通过网络在线交流形式与投资者就公司治理及社会责任 /ESG、经营状况、发展战略、风险防控、投资者保护、三季度报告等投资者关注 的问题进行沟通。欢迎广大投资者积极参与。 特此公告。 ...

山东赛托生物科技股份有限公司 2022 年第三季度报告 证券代码：300583 证券简称：赛托生物 公告编号：2022-077 山东赛托生物科技股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告 中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 1 山东赛托生物科技股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同 | 年初至报告期末 | 年初至报告期末比 | | --- | --- | --- | --- | --- | | | | 期增减 | | 上年同期增减 | | 营业收入（元） | 296,709,591.90 | 14.8 ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 636,242,960.65, representing a 2.03% increase compared to CNY 623,607,764.69 in the same period last year[23]. - The net profit attributable to shareholders of the listed company was CNY 32,339,106.58, a significant increase of 70.17% from CNY 19,003,606.57 in the previous year[23]. - The net profit after deducting non-recurring gains and losses reached CNY 30,750,102.42, marking a 376.30% increase compared to CNY 6,456,016.31 in the same period last year[23]. - Cash flow from operating activities surged to CNY 182,721,185.87, a remarkable increase of 2,024.10% from CNY 8,602,296.58 in the previous year[24]. - Basic earnings per share rose to CNY 0.30, up 66.67% from CNY 0.18 in the same period last year[24]. - Total assets at the end of the reporting period were CNY 3,219,475,133.82, an increase of 8.41% from CNY 2,969,699,298.75 at the end of the previous year[24]. - The net assets attributable to shareholders of the listed company were CNY 1,712,375,060.99, reflecting a 1.76% increase from CNY 1,682,729,774.58 at the end of the previous year[24]. - The weighted average return on net assets was 1.90%, an increase of 0.75% compared to 1.15% in the previous year[24]. Investment and Projects - The company has invested ¥35,998.80 million in the project for an annual production of 700 tons of 9-hydroxyandrostenedione, and ¥23,475.55 million in the steroid intermediates and raw materials project[78]. - The company has adjusted the investment plan, terminating the construction of the 120 tons of 4-ene and 180 tons of dihydroxyprogesterone production lines, focusing on the 700 tons of 9-hydroxyandrostenedione production line[79]. - The company has allocated ¥27,000.00 million of repurposed funds to a new project for steroid intermediates and raw materials, with a total investment of ¥45,091.00 million[79]. - The company has used ¥11,460.00 million of repurposed funds to acquire 100% equity of Runxin Thermal Power[80]. - The annual net profit expected from the "700 tons of 9-hydroxyandrostenedione, 120 tons of 4-androstenedione, and 180 tons of hydroxyprogesterone project" was originally estimated at CNY 472.17 million, but after adjustments, the average annual net profit is now projected to be CNY 159.39 million[84]. - The "steroid intermediates and raw materials project" has completed the construction of three workshops, two warehouses, and a control center, but is still pending some equipment installation due to pandemic-related delays[84]. - The completion deadline for the "steroid intermediates and raw materials project" has been extended to May 1, 2023, with partial construction completed as of June 30, 2022[84]. Subsidiaries and Equity - The subsidiary Disen Bio reported a net profit of CNY 19.85 million, contributing significantly to the company's overall performance[95]. - The subsidiary Sry Pharmaceutical achieved a net profit of CNY 8.99 million, reflecting its role in the company's profitability[95]. - The company holds 100% equity in Disen Bio and 85% in Sry Pharmaceutical, indicating strong control over its key subsidiaries[97][98]. Environmental and Social Responsibility - The company is committed to environmental protection and has invested in reducing pollution during production processes[108]. - The company emphasizes its commitment to environmental protection and sustainable development, focusing on resource efficiency and waste management[148]. - The company actively engages in social responsibility initiatives, contributing to community management and public welfare[147]. - Environmental monitoring is conducted regularly by third parties, with results publicly disclosed[143]. - The company has established an emergency response plan for environmental incidents, which has been filed with local authorities[142]. Share Capital and Stock Management - The company plans not to distribute cash dividends or issue bonus shares[6]. - The company completed the cancellation of 330,500 restricted stocks due to unmet performance targets, reducing the total share capital from 107,252,567 shares to 106,922,067 shares[22]. - The company has implemented a stock incentive plan to enhance the responsibility and mission of its management team[116]. - The stock incentive plan was approved in 2017, granting 1.322 million shares to 47 incentive targets[118]. - The company completed a wastewater treatment facility with a capacity of 4,000 m³/d in June 2016 and another with a capacity of 3,600 m³/d in February 2021[133]. Financial Management and Compliance - The company has not engaged in any entrusted financial management, derivative investments, or entrusted loans during the reporting period[90][91][92]. - The company has not sold any major assets during the reporting period, maintaining its asset base[93]. - The company has maintained transparency in information disclosure, adhering to legal and regulatory requirements[149]. - The company borrowed a total of 9,000,000 RMB from its controlling shareholder, with an interest rate of 7.00%, resulting in an interest expense of 132.42 million RMB for the period[165]. - The financial report for the first half of 2022 was not audited[195].

Financial Performance - The company's operating revenue for 2021 was CNY 1,202,622,703.68, representing a 31.70% increase compared to CNY 913,187,604.30 in 2020[25]. - The net profit attributable to shareholders for 2021 was CNY 36,205,360.05, a significant turnaround from a loss of CNY 179,807,242.83 in 2020, marking a 120.14% improvement[25]. - The basic earnings per share for 2021 was CNY 0.34, compared to a loss of CNY 1.68 per share in 2020, reflecting a 120.24% increase[25]. - The company achieved a revenue of 1,202.87 million yuan and a net profit of 36.21 million yuan, representing a year-on-year growth of 120.14%[62]. - The total operating revenue for 2021 was CNY 1,202.62 million, representing a 31.70% increase compared to CNY 913.19 million in 2020[72]. - The pharmaceutical manufacturing segment accounted for 97.04% of total revenue, with a year-on-year growth of 32.71%[75]. - The sales volume of steroid drug raw materials increased by 35.33% year-on-year, reaching CNY 1,063.10 million[75]. - The company achieved a gross margin of 22.82% in the pharmaceutical manufacturing sector, an increase of 10.63% compared to the previous year[75]. - The company reported a total revenue of 3,594 million CNY for the year 2021[160]. Investment and R&D - The company plans to increase R&D investment to maintain its technological leadership in the industry, while implementing strict confidentiality measures to protect core technologies[9]. - The company has invested over 200 million yuan in R&D, resulting in 42 patents, including 14 invention patents[57]. - R&D expenses reached CNY 49,730,559.44, a 10.49% increase compared to CNY 45,007,850.59 in 2020[84]. - The company is actively working on the registration and production of new high-end specialty APIs, positioning itself for future growth[64]. - The company aims to transition from intermediates to high-end specialty APIs and finished formulations, enhancing its competitive edge in the pharmaceutical sector[131]. - The company plans to increase R&D investment in 2022 to drive innovation and address industry challenges, emphasizing collaboration with key universities and research institutions[137]. Market and Product Strategy - The company aims to enhance its product structure and expand the production scale of high-end intermediates, focusing on respiratory high-end specialty raw materials[12]. - The company is committed to adjusting its product structure and improving the technical content and added value of its products through lean management and technological innovation[12]. - The company is focused on strengthening cooperation with existing customers while actively seeking new clients to ensure sustainable development[7]. - The company is positioned to cover the entire industry chain from intermediates to raw materials and formulations, enhancing its competitive advantage[41]. - The market for assisted reproductive drugs is expanding due to changing national population and fertility policies, presenting significant opportunities[36]. - The company is positioned to become a global production center for steroid hormone raw materials, with domestic production accounting for approximately one-third of the world's total output[35]. Operational Efficiency and Management - The company will optimize its organizational structure and enhance management capabilities to mitigate management risks associated with its accelerated growth[8]. - The company has implemented measures to enhance management efficiency and reduce costs, resulting in significant improvements in production quality and efficiency[67]. - The company has established a competitive R&D and production system for respiratory high-end specialty APIs, with several products ready for mass production[64]. - The company has established stable strategic partnerships with leading pharmaceutical companies, enhancing brand recognition in the industry[59]. - The company has implemented a comprehensive management optimization strategy to improve efficiency and reduce costs[50]. Environmental Commitment - The company emphasizes environmental protection and has implemented measures to reduce pollution and waste emissions in its production processes[11]. - The company is committed to environmental protection and aims to achieve zero environmental pollution incidents while enhancing its green production capabilities[136]. Risks and Challenges - The company is facing industry risks due to increasing competition and rising costs of raw materials, which may impact its performance[6]. - The company acknowledges the risk of investment project failures if market expansion is insufficient, and plans to actively explore markets to absorb new production capacity[12]. - Management risks are anticipated as the company expands its business scope, necessitating optimization of organizational structure and talent management[140]. - The pharmaceutical industry is undergoing significant transformation, with increasing regulatory standards and market consolidation, presenting both challenges and opportunities for the company[35]. Governance and Shareholder Relations - The company has a board of directors consisting of 7 members, including 3 independent directors, which complies with legal and regulatory requirements[149]. - The company emphasizes transparency in information disclosure, utilizing multiple platforms to enhance investor relations[153]. - The company ensures equal treatment of all shareholders, particularly minority shareholders, during voting processes[148]. - The company has not engaged in any related party transactions that could harm the interests of shareholders[157]. - The company has maintained a rigorous approach to governance, adhering to laws and regulations throughout its operations[178]. Employee Management and Compensation - The total number of employees at the end of the reporting period was 1,140, with 739 in production, 182 in technical roles, and 21 in sales[184]. - The company has implemented a performance-based compensation system, aligning employee salaries with market standards and company performance[185]. - A systematic employee training plan was established to enhance employee skills and overall company competitiveness, including various training programs[186]. - The total remuneration for the board of directors, supervisors, and senior management in 2021 amounted to 4.2615 million RMB[171]. Future Outlook - The financial outlook for the upcoming year remains positive, with expectations for continued growth in revenue and market share[165]. - Future growth opportunities are anticipated in the advanced manufacturing sector of pharmaceuticals, particularly in raw materials and high-quality generics[130].

重要内容提示: 山东赛托生物科技股份有限公司 2022 年第一季度报告全文 证券代码：300583 证券简称：赛托生物 公告编号:2022-021 山东赛托生物科技股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度 报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增 | | --- | --- | --- | --- | | | | | 减 | | 营业收入（元） | 253,646,857.08 | 272,376,194.52 | -6.88% | | 归属于上市公司股东的净利润（元） | 12,739,9 ...

证券代码：300583 证券简称：赛托生物 编号：2021-066 山东赛托生物科技股份有限公司 关于参加山东辖区上市公司2021年度投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 为进一步加强与广大投资者的沟通交流，切实提高上市公司透明度、规范运 作和公司治理水平，山东赛托生物科技股份有限公司（以下简称"公司"）将参 加由山东证监局、山东上市公司协会联合举办，深圳市全景网络有限公司承办的 "山东辖区上市公司 2021 年度投资者网上集体接待日"活动，现将有关事项公 告如下： 本次投资者网上集体接待日活动将通过全景网平台线上交流方式举行，投资 者可以登录"全景·路演天下"网站（http://rs.p5w.net）参与本次活动。投 资者与公司互动交流时间为 2021 年 11 月 16 日（星期二）下午 14:00-16:00。 届时公司董事、副总经理、董事会秘书李璐女士、证券事务代表曾庆利女士 及郭一多先生将通过网络在线交流形式与投资者进行沟通交流，欢迎广大投资者 积极参与。 特此公告。 山东赛托生物科技股份有限公司 董事会 ...

Financial Performance - Revenue for Q3 2021 reached ¥258,468,655.81, an increase of 11.37% year-over-year, and total revenue for the year-to-date was ¥882,076,420.50, up 21.66% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2021 was ¥12,578,394.22, representing a significant increase of 204.17% year-over-year, with year-to-date net profit at ¥31,582,000.79, up 164.29%[3] - The basic earnings per share for Q3 2021 was ¥0.1178, an increase of 204.34% year-over-year, while the diluted earnings per share also stood at ¥0.1178, up 205.56%[3] - Total operating revenue for Q3 2021 reached CNY 882,076,420.50, an increase of 21.7% compared to CNY 725,008,466.40 in the same period last year[21] - Net profit for Q3 2021 was CNY 30,207,464.49, a significant recovery from a net loss of CNY 59,283,354.55 in the previous year[22] - Earnings per share for Q3 2021 were CNY 0.2978, compared to a loss per share of CNY 0.4595 in the same quarter last year[23] - The company reported a total comprehensive income of CNY 32,562,901.09 for Q3 2021, recovering from a loss of CNY 59,283,354.55 in the previous year[23] Assets and Liabilities - Total assets as of the end of Q3 2021 were ¥3,048,613,279.71, reflecting a growth of 7.30% from the end of the previous year[3] - The company's total assets increased to CNY 3,048,613,279.71, up from CNY 2,841,295,244.66 year-over-year[19] - Total liabilities rose to CNY 1,324,660,962.86, compared to CNY 1,149,916,239.64 in the previous year, indicating a year-over-year increase of 15.2%[19] - The company's equity attributable to shareholders increased to CNY 1,676,693,530.56, up from CNY 1,643,008,784.70[19] - The company’s total equity attributable to shareholders was ¥1,676,693,530.56, a slight increase of 2.05% from the end of the previous year[3] Cash Flow - The company reported a net cash flow from operating activities of ¥34,619,403.71 year-to-date, which is a decrease of 86.45% compared to the same period last year[3] - The net cash flow from operating activities was 34,619,403.71, a decrease of 86.4% compared to 255,467,635.44 in the previous period[26] - Cash inflow from operating activities totaled 650,380,676.22, down 6.9% from 698,176,828.78 in the previous period[26] - Cash outflow from operating activities increased to 615,761,272.51, up 39.0% from 442,709,193.34 in the previous period[26] - The net cash flow from investing activities was -270,485,660.90, worsening from -123,559,294.95 in the previous period[26] - Cash inflow from financing activities was 468,772,392.51, an increase of 15.7% compared to 405,000,000.00 in the previous period[26] - The net cash flow from financing activities improved to 52,683,921.28, compared to -134,660,452.16 in the previous period[26] - The total cash and cash equivalents at the end of the period was 60,765,676.58, down from 157,087,291.42 in the previous period[26] Shareholder Information - Total number of common shareholders at the end of the reporting period is 12,062[11] - The largest shareholder, Shandong Runxin Investment Co., Ltd., holds 37.11% of shares, totaling 39,802,720 shares[11] - The second-largest shareholder, Mi Chaojie, holds 22.79% of shares, totaling 24,448,000 shares[11] Research and Development - Research and development expenses for the year-to-date increased to ¥3,414.07 million, a rise of 36.26% compared to the same period last year, driven by increased project activity[9] - Research and development expenses for Q3 2021 were CNY 34,140,716.76, compared to CNY 25,054,992.89 in the same period last year, marking a 36.3% increase[22] Tax and Other Liabilities - The company reported a significant increase in tax liabilities, with amounts due rising by 241.02% year-over-year to ¥1,064.59 million, reflecting increased business activity[9] - The company received 4,194,489.51 in tax refunds, significantly up from 994,103.21 in the previous period[26] Inventory and Receivables - The company’s accounts receivable increased by 96.40% year-over-year to ¥19,803.34 million, attributed to higher business volume[8] - Accounts receivable increased to ¥198,033,437.81 from ¥100,833,276.47 year-over-year[17] - Inventory as of September 30, 2021, is ¥533,188,364.38, slightly up from ¥532,404,151.77 at the end of 2020[17] Company Plans and Approvals - The company plans to issue A-shares to specific investors, pending approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission[13] - The company is actively engaging with intermediaries to address inquiries related to the A-share issuance process[14] Reporting and Audit - The company has not undergone an audit for the third quarter report[31] - The report was issued by the board of directors on October 29, 2021[32]

Financial Performance - The company's operating revenue for the first half of 2021 was approximately ¥623.61 million, representing a 26.51% increase compared to ¥492.92 million in the same period last year[24]. - The net profit attributable to shareholders of the listed company reached approximately ¥19.00 million, a significant turnaround from a loss of ¥37.05 million in the previous year, marking a 151.29% improvement[24]. - The basic earnings per share increased to ¥0.18, compared to a loss of ¥0.35 per share in the previous year, reflecting a 151.43% improvement[24]. - The company achieved a revenue of 623.61 million yuan, representing a year-on-year growth of 26.51%[39]. - The net profit attributable to shareholders reached 19.00 million yuan, marking a significant increase of 151.29% compared to the previous year[39]. - The total operating revenue for the first half of 2021 reached CNY 623,607,764.69, an increase of 26.5% compared to CNY 492,919,460.37 in the first half of 2020[184]. - The net profit for the first half of 2021 was CNY 67,555,080.43, a significant increase from CNY 21,881,079.93 in the first half of 2020, representing a growth of 208.5%[188]. Cash Flow and Assets - The net cash flow from operating activities was approximately ¥8.60 million, a decrease of 95.32% compared to ¥183.64 million in the same period last year[24]. - The company's operating cash flow net amount decreased by 95.32% to ¥8.60 million, primarily due to increased cash outflow from operating activities[55]. - Cash and cash equivalents at the end of the reporting period were ¥385.43 million, accounting for 11.87% of total assets, down from 12.12% the previous year[59]. - The cash flow from financing activities showed a net inflow of 104,197,506.47 CNY, compared to a net outflow of -25,375,430.85 CNY in the first half of 2020[195]. - The total cash inflow from operating activities was 253,436,604.83 CNY, slightly up from 237,133,002.07 CNY in the previous year[194]. - The total assets at the end of the reporting period amounted to 1,711.00 million RMB, compared to 1,664.16 million RMB at the end of the previous period, indicating a growth of approximately 2.82%[200]. Investments and R&D - Research and development expenses amounted to 25.71 million yuan, accounting for 4.12% of the total revenue, maintaining a high investment level[39]. - Research and development investment increased by 52.80% to ¥25.71 million from ¥16.82 million, driven by accelerated project progress[55]. - The company plans to increase R&D investment to accelerate the development and registration of new products[95]. - The company is focused on integrating the entire industry chain from intermediates to raw materials and finished formulations, enhancing its market position[48]. Market and Competitive Position - The company has established long-term and stable partnerships with leading enterprises in the steroid drug industry, enhancing its competitive position[45]. - The company is transitioning from a single steroid raw material supplier to a comprehensive biotechnology enterprise[36]. - China's pharmaceutical market is projected to continue growing, driven by increasing health awareness and an aging population[40]. - The company is focused on becoming a full-chain biotechnology enterprise, integrating intermediates, active pharmaceutical ingredients, and formulations[95]. Environmental Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities, indicating a significant focus on environmental compliance[117]. - The company has signed a wastewater treatment service agreement with a local water utility, ensuring compliance with wastewater discharge standards[117]. - The company has implemented measures to monitor and control emissions of various pollutants, including ammonia nitrogen and hydrogen sulfide, ensuring compliance with environmental regulations[117]. - The wastewater treatment system has been upgraded, combining two systems to enhance treatment capacity[119]. Corporate Governance and Shareholder Information - The company has not distributed cash dividends or bonus shares for the half-year period[104]. - The company has established a stock incentive plan to enhance the motivation of its management and key technical personnel[105]. - The largest shareholder, Shandong Runxin Investment Co., Ltd., holds 37.11% of shares, totaling 39,802,720 shares[163]. - The company has maintained compliance with information disclosure regulations to protect the rights of minority shareholders[129]. Risk Management - The company has identified several risks, including national policy and industry risks, and has detailed these in the report[7]. - The company faces risks from industry competition and potential price fluctuations in steroid raw materials[94]. - The company has not engaged in any derivative investments or entrusted loans during the reporting period, maintaining a conservative financial strategy[84][85].